This module uses fundamental data of NervGen Pharma to approximate its Piotroski F score. NervGen Pharma F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of NervGen Pharma Corp. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about NervGen Pharma financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NervGen Pharma Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
NervGen
Piotroski F Score
Market Cap
Enterprise Value
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Average Payables
Capex To Depreciation
Pb Ratio
Free Cash Flow Per Share
Roic
Net Income Per Share
Payables Turnover
Cash Per Share
Pocfratio
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Graham Number
Shareholders Equity Per Share
Capex Per Share
Graham Net Net
Average Receivables
Enterprise Value Over E B I T D A
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Ebt Per Ebit
Effective Tax Rate
Company Equity Multiplier
Return On Capital Employed
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Cash Ratio
Price To Book Ratio
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Return On Assets
Price Fair Value
Return On Equity
Investments
Change In Cash
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Total Cashflows From Investing Activities
Other Cashflows From Financing Activities
Depreciation
Capital Expenditures
Total Cash From Operating Activities
Change To Account Receivables
Change To Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Change To Netincome
Change To Liabilities
Stock Based Compensation
Other Non Cash Items
Issuance Of Capital Stock
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Net Tangible Assets
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Non Current Liabilities Total
Total Liab
Net Invested Capital
Total Current Assets
Net Working Capital
Net Debt
Cash And Short Term Investments
Net Receivables
Other Current Assets
Other Stockholder Equity
Accumulated Other Comprehensive Income
Capital Stock
Intangible Assets
Common Stock
Property Plant And Equipment Net
Property Plant Equipment
Selling General Administrative
Other Operating Expenses
Operating Income
Net Income From Continuing Ops
Ebit
Research Development
Ebitda
Total Operating Expenses
Reconciled Depreciation
Income Before Tax
Net Income Applicable To Common Shares
Depreciation And Amortization
Net Interest Income
Interest Income
Gross Profit
Cost Of Revenue
Total Other Income Expense Net
Income Tax Expense
Probability Of Bankruptcy
Net Debt To EBITDA is likely to climb to 1.07 in 2024, despite the fact that Net Debt is likely to grow to (19 M). At this time, NervGen Pharma's Graham Number is fairly stable compared to the past year.
At this time, it appears that NervGen Pharma's Piotroski F Score is Inapplicable. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
The critical factor to consider when applying the Piotroski F Score to NervGen Pharma is to make sure NervGen is not a subject of accounting manipulations and runs a healthy internal audit department. So, if NervGen Pharma's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if NervGen Pharma's financial numbers are properly reported.
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between NervGen Pharma's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards NervGen Pharma in a much-optimized way.
F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.
Book Value Per Share
(0.0322)
At this time, NervGen Pharma's Book Value Per Share is fairly stable compared to the past year.
NervGen Pharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of NervGen Pharma from analyzing NervGen Pharma's financial statements. These drivers represent accounts that assess NervGen Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of NervGen Pharma's important valuation drivers and their relationship over time.
The Macroaxis Fundamental Analysis modules help investors analyze NervGen Pharma Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NervGen Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NervGen Pharma Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
When running NervGen Pharma's price analysis, check to measure NervGen Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NervGen Pharma is operating at the current time. Most of NervGen Pharma's value examination focuses on studying past and present price action to predict the probability of NervGen Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NervGen Pharma's price. Additionally, you may evaluate how the addition of NervGen Pharma to your portfolios can decrease your overall portfolio volatility.